This week in drug discovery (15-19 January) 

News round-up for 15-19 January by DDW Digital Content Editor Diana Spencer.

With seasonal illnesses running amok in the western hemisphere at the moment, it is perhaps not surprising that this week’s news highlights focus on viruses and immunity.

The top stories:

Antibody cocktail effective against emerging Covid-19 variants

Biotech company ExeVir Bio has revealed new data demonstrating that its antibodies are effective in neutralising currently circulating Covid-19 Omicron variants.

Clinical trial will test novel inhaled TB vaccine

A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin.

Revealed: How Covid-19 variants stay ahead of immune defences

Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL).

Collaborative study to improve flu and Covid-19 vaccine design

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination.

Genetically modified stem cells evade immune rejection

Researchers at the University of Arizona Health Sciences say they are one step closer to understanding immunological rejection, a barrier to regenerative medicine, after genetically modifying pluripotent stem cells to evade immune recognition.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free